Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

09 avr. 2026 08h00 HE | Source: Assembly Biosciences, Inc.

Assembly Biosciences Highlights Presentations on Positive Phase 1b Data for ABI-5366 and ABI-1179 in Recurrent Genital Herpes at ESCMID Global 2026

– Additional Phase 1b data for ABI-5366, including results from monthly dosing cohort, selected for oral presentation –– Phase 1b data from ABI-1179 accepted for late-breaker poster presentation...
09 avr. 2026 04h02 HE | Source: Research and Markets

Pharma B2B ECommerce Global Market Forecast 2026-2032 - Opportunities Lie in Digital Integration, Resilient Supply Chains, Real-time Transparency, and Compliance

Dublin, April 09, 2026 (GLOBE NEWSWIRE) -- The "Pharma B2B eCommerce Market - Global Forecast 2026-2032" report has been added to ResearchAndMarkets.com's offering. In 2025, the Pharma B2B...
07 avr. 2026 10h00 HE | Source: Folia Health

Folia Health Launches App-Based Study to Unlock Novel Real-World Evidence of Symptom Burden and Unmet Need for Patients and Caregivers in CIDP

Folia Health launched a first of it's kind study with argenx to understand the real-world CIDP experience for patients and caregivers.
07 avr. 2026 08h00 HE | Source: FIRST ONSITE

First Onsite launches Life Sciences Division to protect critical environments

KELLIE MATZINGER, MICROBIOLOGY AND STERILIZATION AUTHORITY, LEADS FIRST ONSITE’S NEW LIFE SCIENCES DIVISION. GREENWOOD VILLAGE, Colo., April 07, 2026 (GLOBE NEWSWIRE) -- First Onsite Property...
07 avr. 2026 08h00 HE | Source: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Announces Broad Alignment with FDA on Registration Path for CRB-701 in Second-Line HNSCC and Cervical Cancer

FDA feedback enables Corbus to proceed with proposed registrational study design and endpoints to support potential accelerated approval in second-line HNSCC and cervical cancer Updated CRB-701...
07 avr. 2026 07h00 HE | Source: MediWound Ltd.

MediWound to Present New EscharEx® Data at Leading Wound Care Conferences

MediWound to Present New EscharEx® Data at Leading Wound Care Conferences Data highlights mechanism of action, outcomes in VLUs and DFUs, and comparative advantages over SANTYL® Findings support...
07 avr. 2026 01h00 HE | Source: Sanofi Winthrop Industrie

Communiqué de presse: Le lunsekimig de Sanofi a atteint les critères d’évaluation principal et secondaires clés dans les études respiratoires de phase 2 dans l’asthme et la rhinosinusite chronique avec polypose nasale

Des études de phase 2 sur le lunsekimig ont atteint les critères d’évaluation principaux et secondaires clés dans deux maladies respiratoires
07 avr. 2026 01h00 HE | Source: Sanofi Winthrop Industrie

Press Release: Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP

Phase 2 studies of lunsekimig, a novel bispecific nanobody, met primary and key secondary endpoints in two chronic respiratory conditions.
02 avr. 2026 15h26 HE | Source: MediWound Ltd.

MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million

MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million YAVNE, Israel, April 2, 2026 — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic...
02 avr. 2026 11h58 HE | Source: Research and Markets

Radioligand Therapy Market Expected to Surge to $10.72 Billion by 2030: Upsurge in Cancer Cases Fuelling Industry Growth at 10% CAGR

Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Radioligand Therapy Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report provides comprehensive insights, including...

Page suivante